<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02628769</url>
  </required_header>
  <id_info>
    <org_study_id>CE01-204</org_study_id>
    <secondary_id>2014-003077-42</secondary_id>
    <secondary_id>14/LO/2066</secondary_id>
    <nct_id>NCT02628769</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Anti-inflammatory Effects of Solithromycin in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Single-center, Double-blind, Randomised, Placebo-controlled Crossover Study to Evaluate the Effect of Solithromycin on Airway Inflammation in Male and Female Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Melinta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the potential benefit of a new antibiotic, Solithromycin, for the
      long-term treatment of Chronic Obstructive Pulmonary Disease (COPD). Solithromycin is
      hypothesised to work by reducing inflammation in the lungs of patients with COPD. Stable COPD
      patients will receive treatment with solithromycin for 28 days and comparisons will be made
      between any effects observed with Solithromycin and a placebo. This will include any changes
      in inflammatory proteins, lung function and reported symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is a common and debilitating respiratory
      illness, that kills around 30,000 people annually in the UK. The primary risk factor is
      cigarette smoking, which causes inflammation in the air passages of the lungs. This
      inflammation is irreversible and results in progressive lung destruction. Currently, there
      are no effective anti-inflammatory medications available for COPD.

      Inhalers remain the mainstay of regular treatment for COPD. Macrolide antibiotics however,
      are occasionally used as a supplementary treatment for some patients. They have been shown to
      be anti-inflammatory. However, concerns exist over the development of bacterial resistance to
      such antibiotics. Consequently they are not widely prescribed for COPD. Solithromycin is a
      new macrolide antibiotic, which has been shown to possess superior anti-inflammatory
      properties. Importantly, bacteria are far less likely to develop resistance to this new
      medication.

      The current study will assess the effect of solithromycin as an anti-inflammatory treatment
      for COPD. 30 patients will be recruited to receive 28 days of treatment with solithromycin or
      placebo, followed by a 28 day wash out period (no study medication), before taking a further
      28 days of treatment (the medication not taken first time around, i.e. either solithromycin
      or placebo). This study is a single-centre (Harefield Hospital), double-blind (study team and
      patient are not told what treatment they are taking), randomised (order in which
      solithromycin and placebo are taken), placebo-controlled and has a crossover design (subjects
      take both solithromycin and placebo separately). Sputum, blood and fluid from the nasal
      lining will be periodically sampled to examine any effect on the levels of inflammatory cells
      and proteins during the study. Any changes in lung function parameters or symptoms (COPD
      Assessment Test) will also be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">January 5, 2017</completion_date>
  <primary_completion_date type="Actual">January 5, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Sputum Neutrophils Per mL at 28 Days</measure>
    <time_frame>28 days</time_frame>
    <description>A number of sputum neutrophils per mL after treatment with solithromycin and placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Sputum CXCL8 at 28 Days</measure>
    <time_frame>28 days</time_frame>
    <description>Concentrations of sputum CXCL8 after treatment with solithromycin and placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Sputum IL-6 Before and After Treatment With Solithromycin and Placebo at 28 Days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Sputum MPO Before and After Treatment With Solithromycin and Placebo at 28 Days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Sputum MMP-9 Before and After Treatment With Solithromycin and Placebo at 28 Days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Sputum MCP-1 Before and After Treatment With Solithromycin and Placebo.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Sputum TNF-α Before and After Treatment With Solithromycin and Placebo.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of CXCL8 in Nasal Lining Fluid With Solithromycin and Placebo at 28 Days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 After Treatment With Solithromycin and Placebo at 28 Days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R5-R20 After Treatment at 28 Days</measure>
    <time_frame>28 days</time_frame>
    <description>R5-R20 assessed by impulse oscillometry after treatment with solithromycin and placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Assessment Test (CAT) Scores</measure>
    <time_frame>28 days</time_frame>
    <description>COPD Assessment Test (CAT) scores after treatment with solithromycin and placebo.
score of 0-40 to indicate the impact of the disease, the higher score better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Adult COPD Patients With Treatment-related Adverse Events, as Assessed by CTCAE v4.0.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Outcome: Activity of HDAC2 in Sputum Macrophages From Patients, Before and After Treatment With Solithromycin and Placebo.</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome: Activity of PI3K in Sputum Macrophages From Patients, Before and After Treatment With Solithromycin and Placebo.</measure>
    <time_frame>84 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome: Activity of NF-κB in Sputum Macrophages From Patients, Before and After Treatment With Solithromycin and Placebo.</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome: Levels of the Serum Biomarker C-reactive Protein Before and After Treatment With Solithromycin and Placebo.</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome: Levels of Serum Biomarkers Fibrinogen Before and After Treatment With Solithromycin and Placebo.</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Solithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>28 day treatment with placebo taken once per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solithromycin</intervention_name>
    <arm_group_label>Solithromycin</arm_group_label>
    <other_name>CEM-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. History of cigarette smoking &gt;10 pack-years.

          2. Post-bronchodilator FEV1/FVC of &lt;0.70 and FEV1 of 30-79% of predicted normal value.

          3. Patients on prescribed inhaled corticosteroids can be enrolled.

          4. Females of non-childbearing potential: surgically sterile (e.g. tubal ligation) or at
             least 2 years post-menopausal.

          5. Females of childbearing potential (including females less than 2 years
             post-menopausal) must have a negative pregnancy test at enrollment and must agree to
             use highly effective methods of birth control (i.e. diaphragm plus spermicide or male
             condom plus spermicide, oral contraceptive in combination with a second method,
             contraceptive implant, injectable contraceptive, indwelling intrauterine device,
             sexual abstinence, or a vasectomized partner) while participating in the study and for
             30 days after the last dose of study drug.

          6. The patient must be willing and able to comply with all study visits and procedures.

          7. The patient must be a suitable candidate for oral therapy and be able to swallow
             capsules intact.

          8. The patient must provide written informed consent.

          9. No evidence of active bacterial infection in sputum by qPCR evaluation.

        Exclusion Criteria:

          1. Acute exacerbation of COPD within the previous 60 days or during the washout period of
             the study.

          2. Any condition that could possibly affect oral drug absorption, e.g. gastroenteritis,
             status post gastrectomy, status post bariatric surgery.

          3. Currently taking medication for HIV, chronic hepatitis B, or hepatitis C virus (HCV)
             infection.

          4. Currently taking theophylline or other xanthine medication.

          5. Currently taking warfarin.

          6. Known concomitant infection (pulmonary or otherwise) which would require additional
             systemic antibiotics.

          7. QTc greater than 450 msec for males or females as corrected by the Fridericia formula.

          8. Current use of drugs known to prolong the QT interval, including Class Ia (quinidine,
             procainamide) or Class III (amiodarone, sotalol) antiarrhythmics.

          9. Concomitant use of drugs, foods, or herbal products known to be moderate to potent
             inhibitors of CYP3A4 isozymes: oral antifungal agents (e.g. ketoconazole,
             itraconazole, posaconazole, fluconazole and voriconazole); HIV protease inhibitors
             (e.g. ritonavir and saquinavir), HCV protease inhibitors (e.g. boceprevir and
             telaprevir), nefazodone, fluvoxamine, conivaptan, diltiazem, verapamil, aprepitant,
             ticlopidine, crizotinib, imatinib; grapefruit or grapefruit juice.

         10. Any use within the prior 7 days of drugs or herbal products known to be moderate to
             potent inducers of CYP3A4 isozymes: St. John's Wort, rifampin, rifabutin,
             anti-convulsants (e.g. phenobarbital, carbamazepine, phenytoin, rufinamide),
             modafinil, armodafinil, etraverine, efavirenz, bosentan.

         11. Required current use of drugs with narrow therapeutic indices that are principally
             metabolized by CYP3A4 or transported by P-glycoprotein (P-gp), for which a drug
             interaction with solithromycin could result in higher and possibly unsafe exposures to
             these drugs: e.g. the P-gp substrates digoxin or colchicine and the CYP3A4 substrates
             alfentanil, astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine,
             fentanyl, midazolam, pimozide, quinidine, sirolimus, tacrolimus, everolimus, and
             terfenadine).

         12. History of organ transplant.

         13. Cytotoxic chemotherapy or radiation therapy within the previous 3 months.

         14. Known neuromuscular disorder from clinical history (e.g. myasthenia gravis,
             Parkinson's disease).

         15. Known significant renal, hepatic, or hematologic impairment.

         16. Women who are pregnant or breast feeding

         17. Prior participation in this protocol.

         18. Any investigational drugs taken or investigational devices used within 4 weeks before
             administration of the first dose of the study drug.

         19. History of intolerance or hypersensitivity to macrolide antibiotics.

         20. Any concomitant condition that, in the opinion of the Investigator, would preclude an
             evaluation of a response or make it unlikely that the contemplated course of therapy
             and follow-up could be completed (e.g. life expectancy &lt;30 days).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Barnes, FRS, FMedSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Man, MBBS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Muscle Lab, Respiratory Medicine, Harefield Hospital</name>
      <address>
        <city>Harefield</city>
        <state>Middlesex</state>
        <zip>UB9 6JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <results_first_submitted>October 17, 2019</results_first_submitted>
  <results_first_submitted_qc>December 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 30, 2019</results_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solithromycin</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Macrolide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>First Solithromycin, Then Placebo</title>
          <description>First 28-day treatment of 400 mg Solithromycin taken once a day, then 28-day treatment with placebo taken once per day.</description>
        </group>
        <group group_id="P2">
          <title>First Placebo, Then Solithromycin</title>
          <description>First 28-day treatment with placebo taken once per day, then 28-day treatment of 400 mg Solithromycin taken once a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Wash Out (28 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participant</title>
          <description>All participants cross-over study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.3" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.7" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1</title>
          <description>Lung function parameter</description>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.29" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>COPD Assessment Test (CAT)</title>
          <description>The COPD Assessment Test (CAT) is a questionnaire for people with Chronic Obstructive Pulmonary Disease (COPD). It is designed to measure the impact of COPD on a person's life. The scores from 0–40. Higher scores denote a more severe impact of COPD on a patient's life.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Sputum Neutrophils Per mL at 28 Days</title>
        <description>A number of sputum neutrophils per mL after treatment with solithromycin and placebo.</description>
        <time_frame>28 days</time_frame>
        <population>Due to the early termination of the study, there were too few subjects and data collected to perform statistical analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Sputum Neutrophils Per mL at 28 Days</title>
          <description>A number of sputum neutrophils per mL after treatment with solithromycin and placebo.</description>
          <population>Due to the early termination of the study, there were too few subjects and data collected to perform statistical analysis</population>
          <units>10^6 cells/ml sputum</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="0.76"/>
                    <measurement group_id="O2" value="5.30" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Sputum CXCL8 at 28 Days</title>
        <description>Concentrations of sputum CXCL8 after treatment with solithromycin and placebo.</description>
        <time_frame>28 days</time_frame>
        <population>Due to the early termination of the study, there were too few subjects and data collected to perform statistical analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Sputum CXCL8 at 28 Days</title>
          <description>Concentrations of sputum CXCL8 after treatment with solithromycin and placebo.</description>
          <population>Due to the early termination of the study, there were too few subjects and data collected to perform statistical analysis</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="0.76"/>
                    <measurement group_id="O2" value="4.29" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Sputum IL-6 Before and After Treatment With Solithromycin and Placebo at 28 Days</title>
        <time_frame>28 days</time_frame>
        <population>No data collected for this Outcome due to early termination of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Sputum IL-6 Before and After Treatment With Solithromycin and Placebo at 28 Days</title>
          <population>No data collected for this Outcome due to early termination of the trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Sputum MPO Before and After Treatment With Solithromycin and Placebo at 28 Days</title>
        <time_frame>28 days</time_frame>
        <population>No data collected for this Outcome due to early termination of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Sputum MPO Before and After Treatment With Solithromycin and Placebo at 28 Days</title>
          <population>No data collected for this Outcome due to early termination of the trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Sputum MMP-9 Before and After Treatment With Solithromycin and Placebo at 28 Days</title>
        <time_frame>28 days</time_frame>
        <population>No data collected for this Outcome due to early termination of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Sputum MMP-9 Before and After Treatment With Solithromycin and Placebo at 28 Days</title>
          <population>No data collected for this Outcome due to early termination of the trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Sputum MCP-1 Before and After Treatment With Solithromycin and Placebo.</title>
        <time_frame>28 days</time_frame>
        <population>No data collected for this Outcome due to early termination of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Sputum MCP-1 Before and After Treatment With Solithromycin and Placebo.</title>
          <population>No data collected for this Outcome due to early termination of the trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Sputum TNF-α Before and After Treatment With Solithromycin and Placebo.</title>
        <time_frame>28 days</time_frame>
        <population>No data collected for this Outcome due to early termination of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Sputum TNF-α Before and After Treatment With Solithromycin and Placebo.</title>
          <population>No data collected for this Outcome due to early termination of the trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of CXCL8 in Nasal Lining Fluid With Solithromycin and Placebo at 28 Days</title>
        <time_frame>28 days</time_frame>
        <population>Due to the early termination of the study, there were too few subjects and data collected to perform statistical analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of CXCL8 in Nasal Lining Fluid With Solithromycin and Placebo at 28 Days</title>
          <population>Due to the early termination of the study, there were too few subjects and data collected to perform statistical analysis</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.58"/>
                    <measurement group_id="O2" value="5.14" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 After Treatment With Solithromycin and Placebo at 28 Days</title>
        <time_frame>28 days</time_frame>
        <population>Due to the early termination of the study, there were too few subjects and data collected to perform statistical analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 After Treatment With Solithromycin and Placebo at 28 Days</title>
          <population>Due to the early termination of the study, there were too few subjects and data collected to perform statistical analysis</population>
          <units>litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.16"/>
                    <measurement group_id="O2" value="1.05" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>R5-R20 After Treatment at 28 Days</title>
        <description>R5-R20 assessed by impulse oscillometry after treatment with solithromycin and placebo.</description>
        <time_frame>28 days</time_frame>
        <population>Due to the early termination of the study, there were too few subjects and data collected to perform statistical analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>R5-R20 After Treatment at 28 Days</title>
          <description>R5-R20 assessed by impulse oscillometry after treatment with solithromycin and placebo.</description>
          <population>Due to the early termination of the study, there were too few subjects and data collected to perform statistical analysis</population>
          <units>kiloPascals per liter per second</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.06"/>
                    <measurement group_id="O2" value="0.21" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Assessment Test (CAT) Scores</title>
        <description>COPD Assessment Test (CAT) scores after treatment with solithromycin and placebo.
score of 0-40 to indicate the impact of the disease, the higher score better outcome</description>
        <time_frame>28 days</time_frame>
        <population>Due to the early termination of the study, there were too few subjects and data collected to perform statistical analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Assessment Test (CAT) Scores</title>
          <description>COPD Assessment Test (CAT) scores after treatment with solithromycin and placebo.
score of 0-40 to indicate the impact of the disease, the higher score better outcome</description>
          <population>Due to the early termination of the study, there were too few subjects and data collected to perform statistical analysis</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="4"/>
                    <measurement group_id="O2" value="15" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Adult COPD Patients With Treatment-related Adverse Events, as Assessed by CTCAE v4.0.</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Adult COPD Patients With Treatment-related Adverse Events, as Assessed by CTCAE v4.0.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory Outcome: Activity of HDAC2 in Sputum Macrophages From Patients, Before and After Treatment With Solithromycin and Placebo.</title>
        <time_frame>28 days</time_frame>
        <population>No data collected for this Outcome due to early termination of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Outcome: Activity of HDAC2 in Sputum Macrophages From Patients, Before and After Treatment With Solithromycin and Placebo.</title>
          <population>No data collected for this Outcome due to early termination of the trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory Outcome: Activity of PI3K in Sputum Macrophages From Patients, Before and After Treatment With Solithromycin and Placebo.</title>
        <time_frame>84 days</time_frame>
        <population>No data collected for this Outcome due to early termination of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Outcome: Activity of PI3K in Sputum Macrophages From Patients, Before and After Treatment With Solithromycin and Placebo.</title>
          <population>No data collected for this Outcome due to early termination of the trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory Outcome: Activity of NF-κB in Sputum Macrophages From Patients, Before and After Treatment With Solithromycin and Placebo.</title>
        <time_frame>28 days</time_frame>
        <population>No data collected for this Outcome due to early termination of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Outcome: Activity of NF-κB in Sputum Macrophages From Patients, Before and After Treatment With Solithromycin and Placebo.</title>
          <population>No data collected for this Outcome due to early termination of the trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory Outcome: Levels of the Serum Biomarker C-reactive Protein Before and After Treatment With Solithromycin and Placebo.</title>
        <time_frame>28 days</time_frame>
        <population>No data collected for this Outcome due to early termination of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Outcome: Levels of the Serum Biomarker C-reactive Protein Before and After Treatment With Solithromycin and Placebo.</title>
          <population>No data collected for this Outcome due to early termination of the trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory Outcome: Levels of Serum Biomarkers Fibrinogen Before and After Treatment With Solithromycin and Placebo.</title>
        <time_frame>28 days</time_frame>
        <population>No data collected for this Outcome due to early termination of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Solithromycin</title>
            <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>28 day treatment with placebo taken once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Outcome: Levels of Serum Biomarkers Fibrinogen Before and After Treatment With Solithromycin and Placebo.</title>
          <population>No data collected for this Outcome due to early termination of the trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days for each treatment period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Solithromycin</title>
          <description>28 day treatment of 400 mg Solithromycin taken once a day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>28 day treatment with placebo taken once per day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver tests</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastro-oesophageal reflux</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Derranged LFTs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Puffy eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Louise Donnelly</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 02075947895</phone>
      <email>l.donnelly@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

